Early access
Sign in
Taking people in United StatesPhase 4

Tirzepatide for Weight Loss in Postmenopausal Women After Breast Cancer

Tests tirzepatide in postmenopausal women with obesity and past hormone receptor-positive breast cancer.

Key facts

Who runs it
Weill Medical College of Cornell University
Where
New York, United StatesSee the site
Trial code
Registry title
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Status
Recruiting
Phase
Phase 4
People taking part
30 people, planned
Started
8 Jun 2026
Expected to end
25 Feb 2028
Type of study
Interventional
Treatments tested
  • Tirzepatide
Record updated
22 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for postmenopausal women with obesity who have had hormone receptor-positive breast cancer and finished their main cancer treatment. It tests whether weekly tirzepatide for 6 months is practical.

Age
18 years or older.
Sex
Women only (biologically female).
Disease stage
Hormone receptor-positive (ER and/or PR) breast cancer, stage 0-III. Obesity: BMI 30 kg/m² or higher, or 27.5 kg/m² or higher for people of Asian ancestry. Postmenopausal.
Earlier treatment
Must have finished treatment meant to remove the cancer (surgery, chemotherapy, radiotherapy) at least 12 weeks before joining. Cannot have used a GLP-1 receptor agonist in the last 3 months.
Biomarker or test result
Breast cancer must be ER-positive and/or PR-positive.

Main reasons for not taking part

  • Stage IV breast cancer
  • Using CDK inhibitors or anti-HER2 therapy at the same time
  • Another active cancer that needs treatment
  • Diabetes that needs insulin
  • Contraindication to tirzepatide

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Biologically female
  • Age ≥ 18
  • Obesity as defined by current BMI ≥ 30 kg/m² or ≥ 27.5 kg/m² for individuals of Asian ancestry
  • Postmenopausal as defined by one or more of the following; Age ≥60 years; Age <60 years with amenorrhea for ≥ 1 year; Documented bilateral surgical oophorectomy; Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrolment, and plan to remain on LHRH agonists throughout the trial
  • HR+ (ER and/or PR) stage 0-III breast cancer
  • Completed curative treatment (surgery, chemotherapy, radiotherapy) at least 12 weeks prior to enrolment
  • Insurance approval for tirzepatide or willing to pay out of pocket
  • Willing to provide informed consent and comply with study procedures

Who cannot take part

  • Concomitant use of CDK inhibitors
  • Concomitant use of antiHER2 therapy
  • The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications
  • Treatment with a GLP-1 receptor agonist within the last 3 months
  • Stage IV breast cancer
  • Other active malignancy requiring treatment
  • Diabetes requiring insulin
  • Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol
  • Enrollment in another investigational clinical trial
  • Contraindication to tirzepatide

Where in United States

  • Weill Cornell MedicineNew York, United StatesContact: Sarah Schmitz, MDTaking people

About the trial

What the trial wants to find out

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.

The group in the trial

  • DrugTreatment being tested

    Treatment: Tirzepatide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Plain-language title
Tirzepatide for Weight Loss in Postmenopausal Women After Breast CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 July 2026